Small Interfering RNA (siRNA) Recent Developments

Top Companies in the Small Interfering RNA (siRNA) Market & Their Offerings

What are the Recent Developments in the Small Interfering RNA (siRNA) Market?

• In January 2026, Ribo Life Science, a key player in siRNA therapeutics, successfully went public through an IPO on the Hong Kong Stock Exchange. The company aims to utilize the raised funds to advance its RNA-based drug pipeline into clinical development, targeting cardiovascular, kidney, liver, and metabolic diseases.
• In September 2025, Mabwell Bioscience and Aditum Bio formed a new company, Kalexo Bio, to advance the development of a novel siRNA therapy. Their lead candidate, 2MW7141, demonstrated strong preclinical results in lowering target gene expression linked to lipid control and reducing the risk of atherosclerotic cardiovascular disease in dyslipidemia patients. Both companies plan to jointly progress 2MW7141 into clinical trials.

Supply Chain Analysis

Clinical Trails

• Clinical trials in small interfering RNA (siRNA) are reshaping precision medicine by enabling gene silencing for diseases that were previously hard to treat, with several FDA-approved therapies already in use. Current research is focused on improving delivery beyond the liver and expanding applications in cancer, cardiovascular, and genetic disorders using lipid nanoparticles and GalNAc conjugation.
• Key players: Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Ionis Pharmaceuticals.

Regulatory Approvals

• Small interfering RNA (siRNA) therapies are now an established drug class, with multiple FDA approvals since 2018 for rare genetic disorders and cardiovascular conditions like high cholesterol. Approved treatments include Patisiran, Givosiran, Lumasiran, Inclisiran, Vutrisiran, and Nedosiran, marking strong clinical validation of RNA interference technology.
• Key players: Alnylam Pharmaceuticals, Novartis, Arrowhead Pharmaceuticals.

Patient Support and Services

• Patient support in small interfering RNA (siRNA) therapies is designed to help patients manage complex and high-cost treatments for rare and chronic diseases such as hATTR amyloidosis and hypercholesterolemia. Support programs typically include financial assistance, specialized nursing care, long-term disease monitoring, and premedication to reduce infusion reactions. Regular follow-ups, including vitamin A level monitoring for therapies like patisiran, are also provided.
• Key players involved include Alnylam Pharmaceuticals, Pfizer, and Novartis.

Market Growth

The global small interfering RNA (siRNA) market size was estimated at USD 3.9 billion in 2025 and is predicted to increase from USD 4.52 billion in 2026 to approximately USD 16.91 billion by 2035, expanding at a CAGR of 15.8% from 2026 to 2035.